SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: medwriter who wrote (202)7/9/1997 11:03:00 AM
From: Biomaven   of 10280
 
Medwriter,

I think the Seldane/Allegra analogy is too much to hope for. There we had a known "black box" side-effect, whereas the association of albuterol with increased death rates is much less clear, as is whether levalbuterol would not have this danger. I just can't see the FDA pulling albuterol off the market without definitive studies showing a reduced death rate. (And these studies would be hard because it's a pretty small effect, assuming it actually exists at all).

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News